The incidence of venous thromboembolism(VTE) including deep venous thrombosis(DVT) and pulmonary embolism(PE) increases exponentially with age. Age is an independent risk factor, acute and chronic diseases and factors affecting blood coagulation and anticoagulation equilibrium are also associated with VTE. Homocysteine may be an independent risk factor for occlusive vascular disease. The author summarized the risk factor, mechanism of action, diagnosis and therapy of VTE.

Objective Non-alcoholic fatty liver ( NAFL) is a metabolic disease and levocarnitine can be used to improve the energy metabolism of the patient .This study aimed to evaluate the clinical efficacy of levocarnitine in the treatment of NAFL . Methods We retrospectively analyzed 85 cases of NAFL treated by lifestyle intervention (control group, n=40) or by lifestyle intervention +levo-carnitine medication (medication group, n=45).In addition to lifestyle intervention, the patients in the medication group received oral levocarnitine at 10 mL tid for 4 weeks followed by a reduced dose of 10 mL bid for another 8 weeks. Results Twelve weeks after treat-ment, 37 cases (82.2%) in the medication group showed remarkable improvement and the other 8 failed to respond.In the control group, 23 cases (57.5%) were improved and 17 cases remained unimproved .There were statistically significant differences in the rate of therapeutic effectiveness between the two groups of patients (P<0.01).No adverse effects were observed during the levocarnitine medi-cation. Conclusion Lifestyle intervention +levocarnitine medication can improve NAFL .

Objective The control rate of blood pressure in hypertension patients is very low in our country , while follow-up intervention can significantly improve the situation .This study aimed to evaluate the clinical effects of anti-hypertension under follow-up intervention . Methods From October 2013 to October 2014 , 125 patients with hypertension were chose as the study objectives after first clinical anti-hypertension and were divided into intervention group (follow-up,n=65) and control group(no follow-up,n=60). Comparative analysis was made in blood pressure control , compliance with therapy and cardiovascular event incidence between the two groups after 12 weeks'intervention. Results After 12 weeks, diastolic and systolic blood pressure in intervention group was signifi-cantly lower than that in control group (P<0.05).Significant difference was also found in the compliance with drug-taking between in-tervention group and control group (73.8%vs 43.3%, P<0.01).During the follow-up period, 1 case in the control group suffered stroke and unstable angina pectoris hospitalized for treatment . Conclusion Follow-up intervention after clinical service can improve the efficacy of blood pressure control and encourage the patients to live healthy lifestyle .

Objective:To discuss the influence of bifid triple viable enteric-coated capsules on liver function and inflammatory fac-tor in the patients with non-alcoholic steatohepatitis ( NASH) . Methods:Totally 70 cases of patients with NASH were selected and di-vided into the control group and the observation group at random. The patients in the two groups were all given routine hepatoprotective therapy. The patients in the observation group were additionally given 420mg bifid triple viable enteric-coated capsules, three times a day for 4 weeks. Except for bifid triple viable enteric-coated capsules, the patients in the control group were given the same medical treatment as that in the observation group. The changes of liver function index, serum high sensitivity C reaction protein ( hs-CRP) , IL-6 and IL-8 levels in the two groups before and after the medical treatment were observed and the security was compared. Results:After the 4-week medical treatment, ALT, GGT, serum hs-CRP, IL-6 and IL-8 levels in the two groups were obviously declined than those before the treatment (P<0. 05 or P<0. 01), and the declining rate in the observation group was much higher than that in the control group (P<0. 05). Totally 6 and 4 cases of adverse drug reaction (ADR) respectively appeared in the observation group and the control group during the medical treatment with mild symptom, and the difference was without statistical significance (P>0. 05). Conclusion:Bifid triple viable enteric-coated capsules in the treatment of NASH can obviously reduce the serum hs-CRP, IL-6 and IL-8 levels, inhibit the intrahepatic inflammation and immunologic injury, and improve the liver function index with high security.